文献速递淋巴瘤

老年霍奇金淋巴瘤患者一线治疗:SEER-Medicare人群研究

First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study.
PubMed 文献 · Br J Haematol · 2020-02-23

本研究利用SEER-Medicare 1999至2014年数据,纳入2825例≥65岁新发霍奇金淋巴瘤患者,描述其一线治疗模式。高龄、经济弱势、衰弱、心脏合并症等因素与不接受完整化疗独立相关,提示治疗差异与潜在不平等。

要点

  • 高龄、衰弱、心脏合并症及经济弱势与不接受完整化疗独立相关。
  • Medicaid资格和地区差异提示治疗可能存在不公平。

核心结论

  • 老年霍奇金淋巴瘤患者一线治疗存在显著差异,部分差异可能反映医疗不平等。
  • 即使调整衰弱和心脏合并症后,年龄仍与治疗选择相关,提示终末期照护或共同决策等因素可能影响治疗。

研究设计与样本

  • 基于SEER-Medicare数据库的回顾性人群研究,纳入1999至2014年确诊的2825例≥65岁新发霍奇金淋巴瘤患者。
  • 一线治疗定义为诊断后≤4个月内启动,分为完整化疗方案、部分化疗方案、单药化疗或放疗、未治疗四类。

主要发现

  • 多因素回归显示,高龄、Medicaid双重资格、未婚、衰弱、心脏合并症、既往癌症、较早诊断日期、组织学类型、晚期疾病、B症状和南部地区与不接受完整化疗方案的几率增加独立相关。

临床怎么用

  • 临床医生应认识到老年霍奇金淋巴瘤患者接受完整化疗的比例较低,需综合评估衰弱、合并症及社会经济因素。
  • 治疗决策时应关注可能影响治疗强度的非疾病因素,如经济弱势和地区差异,促进公平医疗。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While Hodgkin lymphoma (HL) is highly curable in younger patients, older patients have higher relapse and death rates, which may reflect age-related factors, distinct disease biology and/or treatment decisions. We described the association between patient, disease and geographic factors and first-line treatment in older patients (≥65 years) with incident HL using Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 1999 to 2014 (n = 2825). First-line treatment initiated at ≤4 months after diagnosis was categorised as: full chemotherapy regimen (n = 699, 24·7%); partial chemotherapy regimen (n = 1016, 36·0%); single chemotherapy agent or radiotherapy (n = 382, 13·5%); and no treatment (n = 728, 25·8%). Among the fully treated, ABVD [doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine]/AVD was most common (n = 635, 90·8%). Adjusted multinomial logistic regression identified factors associated with treatment. Older age, Medicaid dual eligibility, not married, frailty, cardiac comorbidity, prior cancer, earlier diagnosis date, histology, advanced disease Stage, B symptoms and South region were independently associated with increased odds of not receiving full chemotherapy regimens. In conclusion, we found variability in first-line HL treatment for older patients. Treatment differences by Medicaid and region may indicate disparities. Even after adjusting for frailty and cardiac comorbidity, age was associated with treatment, suggesting factors such as end-of-life care or shared decision-making may influence treatment in older patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rodday AM, Hahn T, Kumar AJ, et al. First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. Br J Haematol. 2020. PMID: 32090325. doi:10.1111/bjh.16525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。